Alexion To Start Pivotal Study On Ultomiris For ALS In Q1
Zacks Investment Research | Jan 15, 2020 04:34AM ET
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced plans to start a pivotal phase III study to evaluate its long-acting C5 complement inhibitor, Ultomiris (ravulizumab), in a new indication — amyotrophic lateral sclerosis (ALS). The study will be called CHAMPION-ALS (n~350) and evaluate the efficacy and safety of Ultomiris across a broad ALS patient population. ALS is a neurological disorder characterized by progressive degeneration of nerve cells in the brain and the spinal cord, which control muscles throughout the body.
Alexion submitted an investigational new drug application (IND) for Ultomiris in ALS to the FDA in the fourth quarter of 2019. The company plans to initiate the phase III study in the first quarter of 2020.
The patients in the study will be randomized on a 2:1 basis to receive Ultomiris or placebo every eight weeks after an initial loading dose and may continue to receive their existing standard-of-care treatment for ALS. After 50 weeks, all patients will receive Ultomiris in a two-year, open-label extension phase of the study. The study will be conducted at about 90 sites across North America, Europe and the Asia Pacific.
Alexion’s share price has gained 1% in the past year against the industry ’s decline of 1.8%.
We remind investors that Ultomiris is approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) to be administered every eight weeks. The drug is also approved in the United States for the treatment of atypical hemolytic uremic syndrome (aHUS) in adults and children one month and older.
Ultomiris recorded sales of $168.7 million in the nine months ended Sep 30, 2019.
The label expansion of the drug into additional indications will boost sales further.
Zacks Rank & Other Stocks to Consider
Alexion is currently a Zacks Rank #1 (Strong Buy) stock.
A few similar-ranked stocks in the biotech sector are Anavex Life Sciences Corp. (NASDAQ:AVXL) , ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN) and Celsion Corp. (NASDAQ:CLSN) . You can see .
Anavex’s loss per share estimates have narrowed from 64 cents to 48 cents for 2019 and from 67 cents to 42 cents for 2020 in the past 90 days. The company delivered a positive earnings surprise in three of the trailing four quarters by 0.57%, on average.
Get The News You Want
ASLAN’s loss per share estimates have narrowed from 69 cents to 67 cents for 2019 and from 62 cents to 61 cents for 2020 in the past 90 days. The company delivered a positive earnings surprise in three of the trailing four quarters by 24.65%, on average.
Celsion’s loss per share estimates have narrowed from $1.00 to 94 cents for 2019 and from 77 cents to 66 cents for 2020 in the past 90 days. The company delivered a positive earnings surprise in three of the trailing four quarters by 51.11%, on average.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0% and even +158.9%. This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.